Ask AI
Optimizing CDK Inhibitors

CE / CME

Medical Minute 2–Older Patients With HR+/HER2- MBC​: Optimizing CDK4/6 Inhibitors

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: September 10, 2025

Expiration: March 09, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident are you in understanding the needs of yourelderly patients with HR+/HER2- metastatic breast cancer (MBC) and inimplementing strategies to mitigate disparities in their care?

2.

  • 78-yr-old postmenopausal woman presents to your clinic with increasing fatigue and weight loss ​

    • She has a history of high-risk, node-positive ER+/HER2- EBC (diagnosed 3 yr ago); she underwent surgery, received adjuvant CT and adjuvant radiotherapy, and was started on letrozole with abemaciclib but did not want additional medication and stopped abemaciclib after 6 mo ​

    • She has hypertension, diabetes, and a significant cardiac history requiring amiodarone for antiarrhthymia; her ECOG PS score is 2 ​



  • Imaging notable for findings consistent with MBC, with lesions in bone, mediastinal lymph nodes, and 2 in liver​

  • Liver biopsy confirms MBC: ER 50%, PgR 30%, HER2 1+​

  • ctDNA evaluation notable for lack of ESR1 or PIK3CA mutations​

Which first-line systemic therapy would yourecommend for this patient?